← Back to news
Clinical

APhA 2026: Pharmacists Say GLP-1 Therapies Are Rewriting the Rules of Metabolic Disease

#APhA 2026#GLP-1#metabolic disease#pharmacists#semaglutide#tirzepatide

The 2026 American Pharmacists Association (APhA) Annual Meeting and Exposition in Los Angeles delivered a clear message to the pharmacy profession: GLP-1 receptor agonists have become one of the most broadly consequential drug classes in modern medicine, and the evidence base is expanding faster than many practitioners can track.

From diabetes drug to metabolic platform

Semaglutide, a GLP-1 receptor agonist originally developed for type 2 diabetes, now carries FDA approvals spanning chronic weight management (as Wegovy) and secondary cardiovascular risk reduction. Tirzepatide, a dual GIP/GLP-1 receptor agonist marketed as Mounjaro and Zepbound, has added obstructive sleep apnea to its label. And the pipeline keeps growing — oral formulations, higher-dose options, and entirely new multi-receptor agonists are in various stages of development.

Speakers at APhA 2026 emphasized that this is no longer a story about a diabetes drug with a useful side effect. The GLP-1 class touches cardiology, hepatology, nephrology, pulmonology, and endocrinology — creating a need for pharmacists who understand the full therapeutic landscape.

Clinical evidence highlights

Several sessions highlighted recent data points that underscore the broadening scope:

  • Cardiovascular protection: The SELECT trial established semaglutide's role in reducing major adverse cardiovascular events independent of diabetes status
  • Liver disease: Emerging data shows GLP-1 receptor agonists reducing liver stiffness in patients with metabolic-associated steatotic liver disease (MASLD)
  • Higher dosing: The FDA recently approved a higher-dose Wegovy formulation for patients seeking greater weight loss
  • Oral access: The approval of oral semaglutide for weight management has expanded access for patients who prefer pills over injections

The pharmacist's evolving role

For community and clinical pharmacists, the APhA sessions highlighted practical challenges: managing insurance prior authorizations, counseling patients on dose titration schedules, monitoring for gastrointestinal side effects, and staying current on a regulatory landscape that shifts monthly. With compounding pharmacy access to GLP-1s in flux and new formulations arriving regularly, pharmacists are increasingly the frontline professionals helping patients navigate their options.